Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between 2011-2018.
The latest annual World Preview 2019, Outlook to 2024 comes at one of the most exciting points in the industry’s development. There is significant optimism around the launch of new technologies and the approval of the first cell and gene therapies, resulting in prescription drug sales being forecast to reach $1.18trn in 2024.
- Pfizer will be the leading prescription drug company in 2024 with sales of $51.2bn, ahead of Novartis and Roche
- Keytruda set to be the top selling drug worldwide in 2024, as Humira loses top spot due to adalimumab biosimilar entry in the EU and expected USA biosimilar entry in 2023
- Should Bristol Myers-Squibb complete its intended acquisition of Celgene and forecast projections for a combined portfolio hold, the combined entity would be the 3rd largest pharmaceutical company based on 2024 prescription sales
- Vertex’s triple combination, VX-659 / VX-445 + tezacaftor + ivacaftor, is anticipated to be the most valuable project in the pharmaceutical industry pipeline with an NPV of close to $20bn